Mon panier

Biotinylated Human Claudin-6 Full Length Protein, His,Avitag™&Flag Tag (Nanodisc)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CL6-H85D4-20ug
$1955.00
CL6-H85D4-100ug
$5870.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Application

    1. Cell based assay (FACS or functional assay)
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    Claudin-6, CLDN6

  • Source

    Nanodisc Biotinylated Human Claudin-6 Full Length Protein, His,Avitag™&Flag Tag (CL6-H85D4) is expressed from Baculovirus-Insect cells. It contains AA Ala 2 - Val 220 (Accession # P56747).

    Predicted N-terminus: Met

    Request for sequence
  • Molecular Characterization

    Claudin-6 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus and a Flag tag at the C-terminus followed by an Avi tag (Avitag™). The protein has a calculated MW of 28.6 kDa.

    *The isotype control of empty/mock nanodisc (Cat. No. APO-H81Q5) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Nanodisc membrane protein is wrapped by a synthetic phospholipid bilayer membrane structure, composed of membrane scaffold proteins (MSPs) and phospholipids.

    2. Synthesis Process

      Nanodisc reconstitution is a self-assembly process that starts from purified, detergent-solubilized membrane proteins and reconstitutes them into synthetic phospholipid bilayers stabilized by MSP1D1 membrane scaffold protein. This creates a stable, detergent-free environment that preserves native conformation and biological activity, with excellent homogeneity and full compatibility with cell-based assays such as FACS and binding assays in antibody discovery and screening (ELISA),etc.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >80% as determined by SDS-PAGE.

  • Formulation

    Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-ELISA

     Claudin-6 ELISA

    Immobilized Biotinylated Human Claudin-6 Full Length Protein, His,Avitag™&Flag Tag (Cat. No. CL6-H85D4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-Claudin-6 Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     Claudin-6 SPR

    Anti-Claudin 6 antibody, Human IgG1 captured on Protein A Chip can bind Biotinylated Human Claudin-6 Full Length Protein, His,Avitag&FlagTag (Cat. No. CL6-H85D4) with an affinity constant of 36.5 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Bioactivity-FACS

     Claudin-6 FACS

    2e5 of Anti-Claudin6 CAR-293 cells were stained with 100 μL of 1 μg/mL Biotinylated Human Claudin-6 Full Length Protein, His,Avitag™&Flag Tag (Nanodisc) (Cat. No. CL6-H85D4) and isotype control protein respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

An oncofetal tight junction protein absent in normal adult tissues but aberrantly expressed in ovarian, endometrial, and testicular cancers. Its strict cancer specificity and extracellular accessibility make it an ideal candidate for CAR-T cell therapy and bispecific antibody development.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Claudin 6

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    15 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte